Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $15.00 price target on the stock, down from $19.00.
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play [Seeking Alpha]
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers [Yahoo! Finance]